Form 4: Omada Health Director Jeryl L. Hilleman Reports Acquisition of Restricted Stock Units

Omada Health, Inc. Director Jeryl L. Hilleman reported the acquisition of 9,736 restricted stock units (RSUs) on June 5, 2025, which are set to vest fully on the first anniversary of the grant date.

Summary

• Jeryl L. Hilleman, a Director of Omada Health, Inc. (OMDA), acquired 9,736 shares of Common Stock.
• The transaction occurred on June 5, 2025.
• These shares are in the form of Restricted Stock Units (RSUs), entitling the reporting person to receive one share of Common Stock for each RSU upon vesting.
• The RSUs were acquired at a price of $0, indicating a grant rather than a purchase.
• 100% of these RSUs will fully vest on the first anniversary of June 5, 2025.
• Following this transaction, Jeryl L. Hilleman beneficially owns 9,736 shares.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is generally a positive signal of alignment between management/board and shareholder interests, but it does not contain significant new financial or operational news to warrant a higher score.

Positives

• The acquisition of 9,736 Restricted Stock Units (RSUs) by a director aligns the director's interests with long-term shareholder value.
• The grant of RSUs at a $0 price is a common form of equity compensation, indicating a commitment to retaining key personnel and incentivizing future performance.

Negatives

• No direct negatives are apparent from this Form 4 filing, as it reports a standard equity grant.

Risks

• The value of the RSUs is directly tied to the future performance of Omada Health's common stock, exposing the holder to market price fluctuations.
• Vesting of the RSUs is contingent on continued service, meaning the director must remain with the company for the units to fully vest.

Future Outlook

The vesting schedule of the Restricted Stock Units indicates a future commitment of the director to the company's performance, with full vesting expected on June 5, 2026.

Industry Context

This Form 4 filing reports a standard equity compensation event for a director in a publicly traded company, a common practice across various industries to align management and board interests with shareholders. It does not provide specific insights into broader industry trends.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) at a $0 price is a common practice for director compensation in publicly traded companies, aligning with typical equity incentive plans.
• The vesting schedule (100% on first anniversary) is a standard approach for director RSU grants, similar to practices seen in other public companies for non-employee directors, though specific terms can vary.
• The number of units granted (9,736) would require comparison to the company's specific peer group and compensation philosophy to assess if it is in line with industry averages for a director of a company of Omada Health's size and stage.

Related Party Transactions

• The RSU grant to a director constitutes a standard, disclosed related party transaction as part of the company's compensation plan.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders if the stock price increases.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• Monitoring the vesting of the 9,736 Restricted Stock Units on June 5, 2026.
• Observing future Form 4 filings for Jeryl L. Hilleman and other insiders for further changes in beneficial ownership.

Key Dates

Recommendation

Keywords

Omada Health, OMDA, Form 4, SEC filing, Restricted Stock Units, RSUs, Insider Transaction, Equity Compensation, Director Compensation, Beneficial Ownership